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Abstract 41 
Background. Visceral leishmaniasis (VL), caused by the Leishmania donovani complex, is a 42 
fatal neglected tropical disease that is targeted for elimination in India, Nepal and 43 
Bangladesh. Improved diagnostic tests are required for early case detection and for 44 
monitoring outcome of treatment. Previous investigations using Leishmania lysate antigen 45 
demonstrated that IgG1 response is a potential indicator of clinical status after 46 
chemotherapy. 47 
 Methods. IgG1 or IgG ELISAs with rK39 or lysate antigens, and novel IgG1 rK39 rapid 48 
diagnostic tests (RDTs) were assessed with Indian VL serum samples from the following 49 
clinical groups: paired pre- and  post-chemotherapy (deemed cured); relapsed; other 50 
infectious diseases, and endemic healthy controls. 51 
Results. With paired pre- and post-treatment samples (n = 37 pairs), ELISAs with rK39 and 52 
IgG1-specific conjugate gave a far more discriminative decrease in post-treatment antibody 53 
response when compared to IgG (p <0.0001). Novel IgG1 rK39 RDTs provided strong 54 
evidence for decreased IgG1 response in patients who had successful treatment (p <0.0001). 55 
Furthermore, both IgG1 rK39 RDTs (n = 38) and ELISAs showed a highly significant difference 56 
in test outcome between cured patients and those who relapsed (n = 23) (p <0.0001). RDTs 57 
were more sensitive than corresponding ELISAs. 58 
Conclusions. We present here strong evidence for the use of IgG1 in monitoring treatment 59 
outcome in VL, and the first use of an IgG1-based RDT using rK39 antigen for the 60 
discrimination of post-treatment cure versus relapse in VL. Such an RDT may have a 61 
significant role in monitoring patients and in targeted control and elimination of this 62 
devastating disease. 63 
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 64 
Introduction 65 
In 2012 the World Health Organization (WHO) estimated the global burden of visceral 66 
leishmaniasis (VL) to be 200,000-400,000 cases annually with 20,000-40,000 deaths. The 67 
vast majority of cases occur within the Indian subcontinent (ISC), eastern Africa and Brazil, 68 
with India accounting for an estimated 70% of global cases but with a recent significant 69 
decline [1,2]. In India, VL is caused solely by Leishmania donovani, spread by the vector 70 
Phlebotomus argentipes, and the disease is considered anthroponotic, with no proven 71 
animal reservoirs. Post kala-azar dermal leishmaniasis (PKDL) is a non-life threatening 72 
potential sequela of treated VL, and patients with PKDL have been shown to  be readily 73 
infectious to biting sand flies of the appropriate vector species [3, 4]. 74 
Since 2005 India, Bangladesh and Nepal have been pursuing the elimination of VL as a public 75 
health problem (<1 case per 10,000) [5]; highly endemic blocks persist in the Indian states of 76 
Bihar, Jharkhand and West Bengal [6]. In 2016 approximately 6,250 total cases were 77 
reported, representing a fall of over 50% since 2013 [6]. The elimination programme focuses 78 
on: early case detection, with successful treatment; improved surveillance; and integrated 79 
vector control [5]. Thus, a successful VL control programme requires the implementation of 80 
specific and early diagnosis. 81 
Clinical features of VL are prolonged fever (>14 days), hepatosplenomegaly, anemia, 82 
pancytopenia and weight loss, non-specific symptoms that prevent definitive clinical 83 
diagnosis. Parasitological diagnosis of Leishmania amastigotes is by microscopy of bone 84 
marrow or spleen aspirates, which are high risk procedures. The detection of IgG against 85 
rK39, a fragment of the Leishmania kinesin-like gene [7], has been used with clinical 86 
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presentation to diagnose VL cases; however IgG levels may remain detectable even years 87 
after successful cure and disease clearance, as reported from India [8, 9], Brazil [10] and 88 
Sudan [11]. Furthermore, asymptomatic individuals who are serologically positive far 89 
outnumber clinical cases [12, 13], with only a small proportion of asymptomatics 90 
progressing to active disease, thereby reducing the positive predictive value of the current 91 
rK39 rapid diagnostic test (RDT).  92 
Studies from India and Nepal have reported post-chemotherapy relapse of VL up to and 93 
beyond 12 months following the end of treatment [14, 15]. With liposomal amphotericin B, 94 
a new first line treatment in India, the relapse rate is an estimated 6.7%, with a significant 95 
proportion of patients relapsing between 6 and 12 months after treatment [14, 16]. To 96 
improve the monitoring of treatment outcome of VL, and for control of the disease, WHO 97 
has identified the vital need for a marker of post-chemotherapeutic cure, and the high 98 
priority incorporation of such a biomarker into a point-of-care RDT [17]. 99 
Here, we investigated whether IgG1 detection in combination with rK39 antigen could 100 
improve serological assessment of treatment outcome in VL, particularly to discriminate 101 
cure from relapse. 102 
Methods 103 
Ethics statement  104 
In India, sample collection was approved by the Ethics Committee of Banaras Hindu 105 
University, Varanasi. In Sudan approval was by the Ethical Research Committee, 106 
the Medical and Health Sciences Campus, University of Khartoum and the National Health 107 
Research Ethics Committee, Federal Ministry of Health, Sudan. Written informed consent 108 
was obtained from adult subjects or from the parents or guardians of individuals less than 109 
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18 years of age (who also gave verbal consent). This research was also approved, as part of 110 
the NIDIAG (Syndromic approach to Neglected Infectious Diseases (NID) at primary health 111 
care level) research consortium (https://cordis.europa.eu/project/rcn/97322_en.html), by 112 
the London School of Hygiene and Tropical Medicine Ethics Committee. 113 
 114 
Samples  115 
We selected Indian sera or plasma from archived samples that were collected after 2007 116 
from male and female adults and children in the endemic region of Muzaffarpur, Bihar, India 117 
(Table 1). Indian VL cases had been diagnosed by positive rK39 serology and parasitologically 118 
confirmed by microscopy of splenic or bone marrow aspirates. Indian paired samples were 119 
from parasitologically confirmed VL patients at day of diagnosis (day 0) and when deemed 120 
cured (6 months; n = 40 pairs). Unpaired relapsed sera were from VL patients who had been 121 
treated but sampled at relapse (n = 23). As described below, not all cure pair and relapse 122 
samples were used in every assay. Control samples were from clinically confirmed 123 
tuberculosis cases (n = 10), and from people living in regions endemic and non-endemic for 124 
VL, with no clinical symptoms (EHC and NEHC respectively, n = 10 in each group). We also 125 
used Sudanese serum samples collected in 2011 and 2013, from Gedaref, Sudan. In Sudan, 126 
cases of VL had been diagnosed by microscopy of bone marrow or lymph node aspirates in 127 
conjunction with serological assays. These diagnoses were made according to their 128 
respective national procedures, prior to the present study. Sera/plasma were stored at -129 
80°C until use. Samples were previously assayed against culture-adapted promastigote 130 
lysate (Marlais et al, manuscript submitted). All patients were HIV negative.  131 
 132 
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Antigens  133 
Recombinant rK39 protein was obtained commercially (RAG0061, Rekom Biotech, Spain). L. 134 
donovani whole cell lysates were derived from two strains: culture-adapted 135 
MHOM/IN/80/DD8 promastigote, and MHOM/IN/00/BHU1 that had been cryopreserved as 136 
amastigotes. Both strains were cultured in αMEM (M0644, Sigma Aldrich, UK) supplemented 137 
as previously described [18]. For strain BHU1, the cryopreserved amastigotes were 138 
recovered into αMEM and then passaged once into fresh medium prior to harvesting as 139 
amastigote-derived promastigotes for lysate preparation. The whole cell lysates were 140 
prepared and sonicated as previously described [19].  Sonicates were centrifuged at 14000 x 141 
g for 10 minutes at 4°C, and the supernatants containing lysate antigens stored at -80°C with 142 
protease inhibitor cocktail (P8340, Sigma Aldrich). Protein concentrations of these antigens 143 
were determined using the BCA Protein Assay kit against bovine serum antigen standards 144 
(23227, ThermoFisher Scientific, UK) according to manufacturer’s instructions. 145 
 146 
ELISAs  147 
For optimisation, we used six Sudanese sera (3 high titre, 1 low and 2 negative) with titrated 148 
rK39 antigen; in subsequent assays we used rK39 resuspended at 0.25 μg/ml in coating 149 
buffer (15 mM Na2CO3, 34 mM NaHCO3, pH 9.6). 150 
To compare antigenicity of rK39 and promastigote antigens using Indian sera, and with 151 
separate detection of IgG1 and IgG, each ELISA plate (735–0465, VWR, UK) was divided into 152 
quadrants. The rK39 antigen at 0.25 μg/ml, and culture-adapted promastigote lysates at 2 153 
μg/ml diluted in coating buffer, were used to coat the top and bottom halves respectively of 154 
the same plate at 100 μl/well and incubated at 4°C overnight. Following three washes with 155 
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PBS / 0.05% Tween 20 (PBST), 200 μl/well of blocking buffer (PBS / 2% skimmed milk 156 
powder (Premier Foods, UK)) was applied to the whole plate and incubated for 2 hours at 157 
37°C. Following three washes, 100 μl/well of serum/plasma diluted 1:200 in PBST / 2% milk 158 
(PBSTM) was added, such that the same samples were arranged identically in each 159 
quadrant. Following incubation at 37°C for 1 hour and six washes in PBST, 100 μl/well of 160 
1:5,000 dilution in PBSTM of horse-radish peroxidase (HRP) labelled anti-human IgG1 161 
(ab99774, Abcam, UK) or anti-human IgG (709-035-149, Jackson Immunoresearch, USA) 162 
were added to the left and right halves of the plate respectively. Following incubation at 163 
37°C for 1 hour and six PBST washes, 100 μl/well of substrate solution (50 mM 164 
phosphate/citrate buffer (pH 5.0) containing 2 mM σ-phenylenediamine HCl (P1526, Sigma 165 
Aldrich) and 0.009% H2O2 (216763, Sigma Aldrich) was added to the entire plate and 166 
incubated in the dark. Reactions were stopped by the addition of 100 μl/well of 1M H2SO4 167 
and absorbance was read at 490 nm. Samples were assayed on duplicate plates 168 
simultaneously. 169 
To compare lysates, 2 µg/ml of amastigote-derived promastigote antigen was coated onto 170 
the top half of the plate at 100 µl/well, in place of rK39, and otherwise the assay was 171 
performed as described above. 172 
 173 
Prototype Rapid Diagnostic Tests 174 
Co-authors at Coris BioConcept manufactured the novel IgG1 rK39 rapid diagnostic tests 175 
described here. The RDT is composed of a nitrocellulose strip sensitised with antigen and 176 
containing anti-human IgG1-specific antibody conjugated with colloidal gold, housed within 177 
a plastic cassette with a buffer application well and a test/reading window. The antigen used 178 
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was rK39 at two different concentrations, namely 0.1 mg/ml (0.1rK) and 0.6 mg/ml (0.6rK), 179 
on separate cassettes. Serum/plasma at volumes of 3.5 µl were pipetted onto the sample 180 
application zone in the test/reading window, then 120 µl of buffer solution was dispensed 181 
into the buffer application well. After 15 minutes, a test was deemed valid if a red control 182 
band was present in line with the ‘C’ on the cassette, and deemed positive if a second band 183 
was present in line with the ‘T’. If no band was visible at the ‘T’, then the test was deemed 184 
negative. Change in test line intensity between paired day 0 and 6 month samples (becomes 185 
negative, decreased, no decrease) was assessed visually. The RDTs were read blind without 186 
reference to the ELISA results. 187 
 188 
Statistical analysis 189 
Statistical analysis was performed using Microsoft Excel 2016 (Microsoft Corporation, USA), 190 
Stata 14 (StataCorp, USA) and for ELISA data (2-tailed, paired t-test with 95% confidence 191 
interval) using R [20]. Serum from the same endemic healthy control was included in each 192 
quadrant of each ELISA plate, from which the cut-off was established for each 193 
antigen/detection antibody combination by a mean of the EHC readings plus 3 standard 194 
deviations. Mean ELISA result for each sample was determined from the duplicate assays. 195 
Paired t-tests were used to determine the significance of differences between day 0 and 6 196 
months.  197 
RDT results were compared with defined clinical status to establish sensitivity with exact 198 
confidence intervals calculated with the Clopper-Pearson exact method. A two-sided 199 
Fisher’s exact test was used to compare relapse versus 6 month post-treatment samples 200 
with both RDT types. 201 
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 202 
RESULTS 203 
IgG1 in ELISA is more discriminative than total IgG as an indicator of cure  204 
Figure 1 compares IgG1 and total IgG recognition of rK39 antigen in ELISAs, with 37 paired 205 
samples at day 0 and at 6 months (when deemed to be cured), and with 20 relapsed 206 
samples. With the same group of patients, the IgG1 titres with cured sera (at 6 months) 207 
were more discriminative of clinical status, compared to total IgG. Comparing cure and 208 
relapse data, IgG1 provided better discrimination than IgG, even when the changes from day 209 
0 samples were not considered. With the rK39 antigen, the ELISA readings of cured sera (6 210 
months) were clustered more towards low values when developed with anti-IgG1 (Figure 1): 211 
81.2% (30/37) were below the cut-off value (A490 = 0.214) compared with only 9% (4/37) for 212 
their total IgG (cut-off A490 = 0.413). There was very strong evidence for a difference (p 213 
<0.0001) between IgG1 and total IgG for 6 month cured readings. The ELISAs using the rK39 214 
developed more rapidly than those with promastigote antigen on the same plate and 215 
therefore the times for stopping the reactions across the entire plates were based on their 216 
anti-rK39 reaction intensities (Figure 2). We did not observe any significant differences in the 217 
ELISA performances using the amastigote-derived or culture-adapted promastigote lysates 218 
(Pearson correlation coefficient 0.98, p <0.0001) (Supplementary Figure S1). 219 
 220 
IgG1 rapid diagnostic tests discriminate relapse from cure  221 
In total 254 RDTs were performed, on 89 individual patients (Table 2).  Ten endemic healthy 222 
controls, 10 non-endemic healthy controls and 10 confirmed tuberculosis patients were 223 
negative with both the 0.1rK and 0.6rK RDTs. 224 
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RDT sensitivity for VL (Day 0) was 94.7% (82.3-99.4) and 100% (90.7-100), for 0.1rK RDT and 225 
0.6rK RDT, respectively. Of the 21 samples from patients at relapse, 19 were positive with 226 
0.6rK RDT, and 18 positive with 0.1rK RDT. With both 0.6rK and 0.1rK  RDTs, there was very 227 
strong evidence (p <0.0001) for a difference in test positivity between 6 month samples 228 
from individuals who relapsed versus 6 month samples from individuals who were cured. 229 
In comparison with the IgG1 rK39 ELISA, the 0.6rK IgG1 RDT gave the same positive result 230 
for 17/18 (94.4% sensitive) samples. For the remaining sample, this RDT was positive, and 231 
the ELISA reading was just below the cut-off. For the cure pairs (day 0 and 6 month sample 232 
pairs), 20 of the 26 patients were positive (day 0) by both IgG1 rK39 ELISA and the 0.6rK 233 
IgG1 RDT, and decreased to negative at 6 months. Four of the other patients were negative 234 
by ELISA at both time points but were positive by the RDT at day 0 and negative at 6 235 
months; the remainder were positive by the RDT at both time points. Thus, the RDTs, which 236 
use more concentrated sample, were overall somewhat more sensitive than the 237 
corresponding ELISAs. 238 
 239 
DISCUSSION 240 
Improved diagnostics for VL are required to discriminate between post-treatment cure 241 
versus relapse, and to predict progression from asymptomatic carrier to active VL. There is 242 
also a need for diagnostics to distinguish PKDL from other dermatological conditions, and to 243 
detect VL in HIV co-infected patients who are immunocompromised [21].  244 
Since its early validation for VL diagnosis [22], rK39 antigen used in either ELISA or RDT 245 
format has been used with IgG detection. However, IgG levels can remain elevated for 246 
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several years after successful treatment [8], whereas IgG1 may decline rapidly in the 247 
absence of sustained and appropriate antigenic stimulus [23, 24]. Here, we describe the 248 
capacity of rK39 with IgG1 level detection to characterise the post-treatment clinical status 249 
of Indian VL. We demonstrated the greater discriminatory potential of IgG1 compared to 250 
IgG, as an indicator of post-chemotherapeutic outcome in VL. We have adapted the IgG1 251 
rK39 assay to an easy to manufacture, point-of-care, reproducible, rapid and inexpensive 252 
test of cure for VL. 253 
ELISA comparison between IgG and IgG1 against rK39 demonstrated that with IgG1 there 254 
was a significantly greater decrease in response following cure (p <0.0001, Figure 1), 255 
supporting the continued development of IgG1-based diagnostics [19]. Paired samples from 256 
cured patients and non-paired samples from patients who relapsed allowed evaluation of 257 
the IgG1 rK39 RDTs. In support of previous observations [19], the majority of 6 month cured 258 
samples were negative, with a significant difference between cured and relapsed individuals 259 
(p <0.0001). Thus, the IgG1 rK39 RDT provides a potential point-of-care means of serological 260 
assessment of treatment success [25]. However, this does not obviate the need for 261 
concomitant clinical evaluation. 262 
It is not known whether the individuals deemed to be cured at 6 months remained free from 263 
relapse thereafter. In one study, most patients who relapsed did so between 6 and 12 264 
months post-treatment [14]. Therefore, as 14 (0.1rK) and 12 (0.6rK) of 38 patients deemed 265 
cured at 6 months were positive by IgG1, albeit the majority with decreased signal strength 266 
(Table 2), further validation of the IgG1 rK39 RDT, at 12 or 18 month clinical and serological 267 
follow-up would be required to determine the relapse rate in comparison with the rate 268 
among the RDT negative patients deemed cured.  269 
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In terms of future application within a clinical environment, an optimum rK39 concentration 270 
will be required. The 0.1 mg/ml concentration produced some negative results and on visual 271 
inspection positive test bands were less clear than with the 0.6rK test; the 0.6 mg/ml 272 
concentration did not cause increased background or false positives with controls. However, 273 
considering the greater cost of manufacture involved it would be appropriate to evaluate 274 
intermediate concentrations. Pilot trials indicate that the IgG1 RDT is directly applicable to 275 
3.5 µl of finger-prick whole blood in the field (unpublished observations).  276 
This is the first report of the use of rK39 with detection of IgG1. We show that this 277 
combination gives a better discrimination between cure and relapse than using IgG, and 278 
that this assay can be adapted into a low cost, point-of-care (POC) RDT format. Similarly, 279 
POC RDTs are required to identify those asymptomatic serologically positive individuals who 280 
are most likely to progress to active disease, and PKDL patients with non-specific 281 
dermatological clinical presentations. The implementation of such POC RDTs within 282 
discriminative case finding initiatives would be of significant benefit in the ISC as it prepares 283 
for a post-elimination environment, in which effective diagnostic surveillance is critical.  284 
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 368 
Table 1: Indian samples used in ELISAs and/or RDTs.  369 
Sample n a Description 
Cured, paired 
samples 
 
40 pairs From parasitologically confirmed VL patients at day of 
diagnosis (day 0) and when deemed cured (6 months).  
Relapsed  23 VL treated and subsequently relapsed. Sampled at the time 
of relapse diagnosis. 
Endemic healthy 
controls 
10 Serum from patients living in regions endemic for VL, with no 
clinical symptoms. 
Non-endemic 
healthy controls 
10 Serum from individuals living in regions non-endemic for VL, 
with no clinical symptoms. 
TB  10 Serum from patients with clinically confirmed tuberculosis. 
a Not all samples were used with all assays (see Results). 370 
 371 
 372 
 373 
 374 
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Table 2: Results of Indian VL and control sera with IgG1 rK39 RDT. rK39 was used at 0.1mg/ml 379 
(0.1rK) and 0.6mg/ml (0.6rK) 380 
Sample types Positive/total (%) 
Cured VL paired samples 
(n = 38) 
Day 0  6 monthsa 0.1rK 0.6rK 
Positive  Negative 22/38 
(57.9%) 
26/38 
(68.4%) 
Decrease 8/38  
(21.1%) 
7/38  
(18.4%) 
No decrease 6/38 
(15.8%) 
5/38 
(13.2%) 
Negative Negative 2/38  
(5.2%) 
0/38 
(0%) 
Positive 0/38 
(0%) 
0/38 
(0%) 
Unpaired samples   
Relapse VL samples (n = 21) 18/21 (85.7%) 19/21 (90.5%) 
Endemic Healthy Control (n = 10) 0/10 0/10 
Non-Endemic Healthy Control (n = 10) 0/10 0/10 
Tuberculosis patients’ samples (n =10) 0/10 0/10 
a 6 month reading is test line intensity assessed visually compared to day 0. 381 
 382 
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Figure 1. Decrease in IgG1 levels of cured patients was more evident and consistent than 386 
the decline in total IgG, by ELISA. ELISA results for the rK39 antigen with cured VL paired 387 
samples (n = 37 pairs) and relapse samples (n = 20). * indicates very strong evidence for a 388 
difference (paired t-test p<0.0001). Strong evidence was also seen between IgG1 and IgG in 389 
6 month cured samples (p<0.0001, not depicted).  390 
 391 
Figure 2. Example of ELISA plate quadrants. CP, cured paired serum samples at day 0 (pre-392 
treatment) and at 6 months after treatment (patients deemed cured); EHC, endemic healthy 393 
control; R, patient deemed relapsed.  394 
 395 
Supplementary Figure S1. Comparative IgG1 ELISA absorbance values obtained using active 396 
VL, cured VL and relapsed VL patients’ serum samples against amastigote-derived and 397 
culture-adapted promastigotes lysate antigens. Pearson r = 0.98; p = <0.0001, for lack of 398 
significant difference. 399 
 400 
